TPX2

Across TCGA pan-cancer cohorts, TPX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TPX2 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher TPX2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TPX2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where TPX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.941	0.629	.010	19	view →
LUAD	OS	Tertile	II,III,IV	0.320	0.792	.020	4	view →
CCRCC	OS	Tertile	II,III,IV	0.365	1.000	.014	2	view →
HNSC	OS	Median	III,IV	0.791	0.542	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TPX2–LSCC (OS)

Open the LSCC breakdown →